Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials
Yan JH, Guan BJ, Gao HY, Peng XE
Medicine · 90 citations
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Natural Science Foundation of China
- Grants
- National Natural Science Foundation of China (81473047)
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2018-09-01 · Medicine (Baltimore) · vol. 97 · issue 37 · p. e12271
- Publisher
- Wolters Kluwer
- Cited
- 137 citations · more than 99% of similar papers · 9.5× the field average
- Impact
- Top 10% most cited in its field
- References
- 48 works
- Access
- Open access (journal) · CC-BY-NC
- Research areas
- Liver Disease Diagnosis and Treatment · Fatty Acid Research and Health · Liver Disease and Transplantation
- Keywords
- Medicine, Polyunsaturated fatty acid, Cochrane Library, Meta-analysis, Internal medicine, Nonalcoholic fatty liver disease, Fatty liver, Randomized controlled trial, Gastroenterology, Insulin resistance, Publication bias, Adverse effect, Fatty acid, Disease, Insulin, Biochemistry, Biology
- MeSH
- humans, insulin resistance, blood glucose, fatty acids, omega-3, triglycerides, liver function tests, body weights and measures, dietary supplements, randomized controlled trials as topic, non-alcoholic fatty liver disease
4 authors
From CN
- Jianhui YanFujian Medical University; Fujian Provincial Cancer Hospital
- Bingjie GuanFujian Medical University
- Haiyan GaoFujian Medical University
- Xian‐E Peng · correspondingFujian Medical University
Abstract
Background
Clinical trials examining the therapeutic benefit of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on nonalcoholic fatty liver disease (NAFLD) have reported inconsistent results. We performed a meta-analysis of randomized controlled trials (RCTs) examining the effect of ω-3 PUFA supplementation on NAFLD, and provide substantial evidence on whether ω-3 PUFA supplementation has a favorable effect for treating NAFLD.
Methods
We searched the PubMed, Cochrane Library, Springer Link, China National Knowledge Infrastructure (CNKI), Wanfang, and Chinese Scientific and Technological Journal (VIP) databases for RCTs on oral ω-3 PUFA supplementation in patients with NAFLD. The data were pooled; meta-analyses were conducted using random-effect or fixed-effect models.
Results
Eighteen studies involving 1424 patients were included. We found a significant benefit for ω-3 PUFAs vs control for liver fat, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglycerides, insulin resistance, and glucose. However, there was significant interstudy heterogeneity. Subgroup and regression analyses showed no significantly clear methodologic discrepancy. Publication bias and serious adverse events were not detected.
Conclusions
Our meta-analysis suggests that ω-3 PUFA supplementation may decrease liver fat and hepatic enzyme parameters. However, more large-scale, well-designed RCTs are needed to confirm the effect of ω-3 PUFA supplementation on these parameters.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.